CXCL8 and COVID-19: The consistent upregulation of CXCL8 across the SARS-CoV-2 ancestral strain and variants, along with elevated IL-8 release from MKs exposed to SARS-CoV-2 variants and in COVID-19 patient plasma, underscores its potential as a biomarker for disease severity.